Deciphering the Exposome by Metabolomic Technology in Breast Cancer
EXPOMET aims to revolutionize understanding of environmental contaminants and their role in breast cancer through innovative mass spectrometry-based exposome assessment and high-throughput monitoring.
Projectdetails
Introduction
EXPOMET proposes a pioneering mass spectrometry-based platform for omic-scale assessment of chemical exposures. EXPOMET will revolutionize our perception of environmental contaminants and the influence these have on breast cancer (BC).
Background
In our ageing society, the incidence of chronic disease is constantly rising; yet, environmental drivers of disease susceptibility are poorly understood. Measuring the myriad of chemicals that humans are constantly exposed to is immensely challenging; and identifying interactions and the molecular pathways that are disrupted is an even more complex task.
To address this issue, the concept of the exposome, i.e., the totality of chemical exposures and the biological effects thereof, was proposed. Innovative analytical technology, however, is lacking and remains the major limitation in this emerging field.
Objectives
EXPOMET aims to establish new avenues towards a comprehensive sequencing of the exposome and illuminating the role played in the etiology of BC. Affecting 1 in 8, BC is the most common cancer in European women.
Methodology
Novel workflows will overcome current limitations and enable high-throughput exposure and effect monitoring of a vast number of environmentally relevant chemicals. The developed cutting-edge methods will be applied, and critically evaluated, in the first exposome-wide association (ExWAS) study on BC.
A deeper understanding of the toxicological impact of co-exposure will be obtained from ensuing functional, systems-level experiments. Breakthrough metabolomic-guided pathway mapping and activity-screening technology will be utilized for investigating causative events.
Impact
The project will provide unique insights into the impact of chemical exposure on the etiology of BC and ground-breaking exposomic technology. EXPOMET will revolutionize viewpoints on environmental contaminants and the influence these have on chronic disease.
Expertise
The PI has a uniquely interdisciplinary expertise to address the multi-facets of this exposome approach.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.937.489 |
Totale projectbegroting | € 2.937.489 |
Tijdlijn
Startdatum | 1-3-2023 |
Einddatum | 29-2-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITAT WIENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Functional characterization of the colorectal cancer metastasis microbiomeThe METABAC project aims to investigate the functional roles of bacteria in colorectal cancer metastasis using innovative platforms to uncover their impact on cancer progression and potential therapeutic targets. | ERC Starting... | € 1.499.894 | 2024 | Details |
Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and DiagnosisEpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors. | ERC Starting... | € 1.500.000 | 2024 | Details |
Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomicsThe CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms. | ERC Starting... | € 2.481.640 | 2024 | Details |
Epigenetic profiling of menstrual blood for precision cancer detection and preventionThe EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers. | ERC Proof of... | € 150.000 | 2024 | Details |
Spatial Quantification of Cellular Metabolism in the Tumor Immune MicroenvironmentThis project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment. | ERC Starting... | € 1.497.756 | 2023 | Details |
Functional characterization of the colorectal cancer metastasis microbiome
The METABAC project aims to investigate the functional roles of bacteria in colorectal cancer metastasis using innovative platforms to uncover their impact on cancer progression and potential therapeutic targets.
Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosis
EpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors.
Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomics
The CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms.
Epigenetic profiling of menstrual blood for precision cancer detection and prevention
The EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers.
Spatial Quantification of Cellular Metabolism in the Tumor Immune Microenvironment
This project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
DETACT - Detection of Enzymes and muTAtions for Cancer TreatmentCytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen. | Mkb-innovati... | € 215.845 | 2019 | Details |
Remote SWEATSkin PATCH for Monitoring Breast Cancer Therapeutic ResponseSWEATPATCH aims to develop a non-invasive, real-time monitoring system using sweat VOCs to personalize breast cancer treatment and improve patient outcomes through innovative technology. | EIC Pathfinder | € 2.670.933 | 2024 | Details |
DETACT - Detection of Enzymes and muTAtions for Cancer Treatment
Cytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen.
Remote SWEATSkin PATCH for Monitoring Breast Cancer Therapeutic Response
SWEATPATCH aims to develop a non-invasive, real-time monitoring system using sweat VOCs to personalize breast cancer treatment and improve patient outcomes through innovative technology.